GRM5 and dementia: In this view, besides the evidence suggesting the mGluR5-NMDAR-C5aR that participates in the loss of memory and synaptic weakening that typify dementia [86], Spurrier and colleagues in 2022 demonstrated that treatment with the mGlu5 silent allosteric modulator BMS-984923 reduces the β amyloid-induced changes of synaptic signalling also preserving the glutamate transmission to physiological level [87].